California’s Office of Health Care Affordability has released revised emergency regulations implementing AB 1415, significantly expanding reporting requirements for private equity and healthcare investors.
The September draft regulations retain many provisions from the May 15 proposed rules while introducing several significant changes affecting private equity sponsors, hedge funds, and management services organisations.
Governor Newsom signed AB 1415 into law on October 11, 2025, with the legislation taking effect on January 1, 2026, setting the stage for a major shift in healthcare transaction oversight.
Since the law’s passage, stakeholders across the California healthcare sector had been awaiting draft regulations from OHCA to clarify notice and clearance requirements for private equity firms and MSOs involved in certain transactions.
OHCA published its first set of anticipated proposed regulations on May 15, 2026, and those rules, if finalised as drafted, would significantly expand the agency’s material change transaction reporting regime.
The September draft goes further still, with overarching themes including the expansion of filing requirements and categories, a heightened focus on control over healthcare entities, and expanded disclosure requirements and production burdens.
Private equity and hedge fund disclosures will now extend to healthcare entities and MSOs directly or indirectly owned, controlled, or financed by participating asset managers and funds.
Organisational chart requirements also reach entities controlled by or under common control with the ultimate parent or its shareholders, broadening OHCA’s visibility into investor control and transaction structures considerably.
The September draft adds a new requirement to disclose certain options, compensation, and other financial incentives for officers, directors, and persons with management or operational responsibility, including incentives contingent on closing.
For investors and providers operating in the California healthcare sector, prior analyses conducted under the May draft may no longer be sufficient given the scope of these changes.
Pending or anticipated transactions may require renewed assessment of notice obligations, timing, costs, and deal value as the regulations move through Office of Administrative Law review.
The revised rules signal a clear intent by California regulators to gain deeper visibility into the financial structures and relationships that underpin private equity involvement in the state’s healthcare market.